Compound preparation for treating depression

Abstract

The invention discloses a compound preparation for treating depression with the traditional antidepressant and curcumin as active components; the traditional antidepressant is a nonselective reuptake inhibitor or a selective 5-hydroxytryptamine reuptake inhibitor, wherein the nonselective reuptake inhibitor is desipramine, the selective 5-hydroxytryptamine reuptake inhibitor is fluoxetine, and the mass ratio of the traditional antidepressant to the curcumin can concretely be 2:1 or 4:1. In the compound preparation for treating the depression, low dosage curcumin and low dosage desipramine or fluoxetine are combined, thereby counteracting the adverse effects caused by blood sugar rise and displaying stronger antidepressant activity, and therefore, the compound preparation has good application prospect.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a compound preparation for treating depression. Background technique [0002] Depression and anxiety, a disease of the central nervous system, have become major diseases that threaten human health around the world. Although a variety of medications are available, mainly antidepressants including non-selective reuptake inhibitors such as desipramine, imipramine, amitriptyline, monoamine oxidase inhibitors (MAOIs) such as phenelzine, and The third-generation antidepressants are selective serotonin reuptake inhibitors fluoxetine, sertraline, etc., but these drugs have different disadvantages that limit their use. The antidepressants of non-selective reuptake inhibitors have slow onset of action and many side effects, including the side effects of easily causing blood sugar elevation, which limit their use; and serotonin reuptake inhibitors, in addition to the above problems, are also expensive...

AI Technical Summary

Problems solved by technology

Although a variety of medications are available, mainly antidepressants including non-selective reuptake inhibitors such as desipramine, imipramine, amitriptyline, monoamine oxidase inhibitors (MAOIs) such as phenelzine, and The third-generation antidepressants are selective serotonin reuptake inhibitors fluoxetine, sertraline, etc., but these drugs have different disadvantages that limit their use

The antidepressants of non-selective reuptake inhibitors have slow onset of action and many side effects, including the side effects of easily causing blood sugar elevation, which limit their use; and serotonin reuptake inhibitors, in addition to the above problems, are also expensive , not suitable for long-term use

Images